<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation</title>
				<funder ref="#_5ugWAKg">
					<orgName type="full">National Science Foundation for Post-doctoral Scientists of China</orgName>
				</funder>
				<funder ref="#_KqX2b5e #_EuGMUBt">
					<orgName type="full">Department of Science and Technology of Zhejiang Province</orgName>
				</funder>
				<funder ref="#_rAe8Twq #_G3YUk6f #_hEch2jj #_nv45Fm6">
					<orgName type="full">National Natural Science Foundation of China</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Weiyang</forename><surname>Lou</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Program of Innovative Cancer Therapeutics</orgName>
								<address>
									<addrLine>Weiyang Lou</addrLine>
									<settlement>Jing Chen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Program of Innovative Cancer Therapeutics</orgName>
								<orgName type="department" key="dep2">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep3">Department of Surgery</orgName>
								<orgName type="department" key="dep4">First Affiliated Hospital</orgName>
								<orgName type="institution" key="instit1">Col- lege of Medicine</orgName>
								<orgName type="institution" key="instit2">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Key Laboratory of Organ Transplantation</orgName>
								<address>
									<postCode>310003</postCode>
									<settlement>Hangzhou Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Ministry of Public Health</orgName>
								<orgName type="institution">Key Laboratory of Combined Multi-organ Transplantation</orgName>
								<address>
									<postCode>310000</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jing</forename><surname>Chen</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">The First Hospital of Jiaxing</orgName>
								<address>
									<postCode>314000</postCode>
									<settlement>Jiaxing Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">First Affiliated Hospital</orgName>
								<orgName type="institution">Jiaxing University</orgName>
								<address>
									<postCode>314000</postCode>
									<settlement>Jiaxing Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bisha</forename><surname>Ding</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Program of Innovative Cancer Therapeutics</orgName>
								<address>
									<addrLine>Weiyang Lou</addrLine>
									<settlement>Jing Chen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Program of Innovative Cancer Therapeutics</orgName>
								<orgName type="department" key="dep2">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep3">Department of Surgery</orgName>
								<orgName type="department" key="dep4">First Affiliated Hospital</orgName>
								<orgName type="institution" key="instit1">Col- lege of Medicine</orgName>
								<orgName type="institution" key="instit2">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Key Laboratory of Organ Transplantation</orgName>
								<address>
									<postCode>310003</postCode>
									<settlement>Hangzhou Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Ministry of Public Health</orgName>
								<orgName type="institution">Key Laboratory of Combined Multi-organ Transplantation</orgName>
								<address>
									<postCode>310000</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Danni</forename><surname>Chen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Program of Innovative Cancer Therapeutics</orgName>
								<address>
									<addrLine>Weiyang Lou</addrLine>
									<settlement>Jing Chen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Program of Innovative Cancer Therapeutics</orgName>
								<orgName type="department" key="dep2">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep3">Department of Surgery</orgName>
								<orgName type="department" key="dep4">First Affiliated Hospital</orgName>
								<orgName type="institution" key="instit1">Col- lege of Medicine</orgName>
								<orgName type="institution" key="instit2">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Key Laboratory of Organ Transplantation</orgName>
								<address>
									<postCode>310003</postCode>
									<settlement>Hangzhou Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Ministry of Public Health</orgName>
								<orgName type="institution">Key Laboratory of Combined Multi-organ Transplantation</orgName>
								<address>
									<postCode>310000</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Huilin</forename><surname>Zheng</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Program of Innovative Cancer Therapeutics</orgName>
								<address>
									<addrLine>Weiyang Lou</addrLine>
									<settlement>Jing Chen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Program of Innovative Cancer Therapeutics</orgName>
								<orgName type="department" key="dep2">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep3">Department of Surgery</orgName>
								<orgName type="department" key="dep4">First Affiliated Hospital</orgName>
								<orgName type="institution" key="instit1">Col- lege of Medicine</orgName>
								<orgName type="institution" key="instit2">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Key Laboratory of Organ Transplantation</orgName>
								<address>
									<postCode>310003</postCode>
									<settlement>Hangzhou Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Ministry of Public Health</orgName>
								<orgName type="institution">Key Laboratory of Combined Multi-organ Transplantation</orgName>
								<address>
									<postCode>310000</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Donghai</forename><surname>Jiang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Program of Innovative Cancer Therapeutics</orgName>
								<address>
									<addrLine>Weiyang Lou</addrLine>
									<settlement>Jing Chen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Program of Innovative Cancer Therapeutics</orgName>
								<orgName type="department" key="dep2">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep3">Department of Surgery</orgName>
								<orgName type="department" key="dep4">First Affiliated Hospital</orgName>
								<orgName type="institution" key="instit1">Col- lege of Medicine</orgName>
								<orgName type="institution" key="instit2">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Key Laboratory of Organ Transplantation</orgName>
								<address>
									<postCode>310003</postCode>
									<settlement>Hangzhou Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Ministry of Public Health</orgName>
								<orgName type="institution">Key Laboratory of Combined Multi-organ Transplantation</orgName>
								<address>
									<postCode>310000</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Liang</forename><surname>Xu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Program of Innovative Cancer Therapeutics</orgName>
								<address>
									<addrLine>Weiyang Lou</addrLine>
									<settlement>Jing Chen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Program of Innovative Cancer Therapeutics</orgName>
								<orgName type="department" key="dep2">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep3">Department of Surgery</orgName>
								<orgName type="department" key="dep4">First Affiliated Hospital</orgName>
								<orgName type="institution" key="instit1">Col- lege of Medicine</orgName>
								<orgName type="institution" key="instit2">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Key Laboratory of Organ Transplantation</orgName>
								<address>
									<postCode>310003</postCode>
									<settlement>Hangzhou Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Ministry of Public Health</orgName>
								<orgName type="institution">Key Laboratory of Combined Multi-organ Transplantation</orgName>
								<address>
									<postCode>310000</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chang</forename><surname>Bao</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Program of Innovative Cancer Therapeutics</orgName>
								<address>
									<addrLine>Weiyang Lou</addrLine>
									<settlement>Jing Chen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Program of Innovative Cancer Therapeutics</orgName>
								<orgName type="department" key="dep2">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep3">Department of Surgery</orgName>
								<orgName type="department" key="dep4">First Affiliated Hospital</orgName>
								<orgName type="institution" key="instit1">Col- lege of Medicine</orgName>
								<orgName type="institution" key="instit2">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Key Laboratory of Organ Transplantation</orgName>
								<address>
									<postCode>310003</postCode>
									<settlement>Hangzhou Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Ministry of Public Health</orgName>
								<orgName type="institution">Key Laboratory of Combined Multi-organ Transplantation</orgName>
								<address>
									<postCode>310000</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Guoqiang</forename><surname>Cao</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Program of Innovative Cancer Therapeutics</orgName>
								<address>
									<addrLine>Weiyang Lou</addrLine>
									<settlement>Jing Chen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Program of Innovative Cancer Therapeutics</orgName>
								<orgName type="department" key="dep2">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep3">Department of Surgery</orgName>
								<orgName type="department" key="dep4">First Affiliated Hospital</orgName>
								<orgName type="institution" key="instit1">Col- lege of Medicine</orgName>
								<orgName type="institution" key="instit2">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Key Laboratory of Organ Transplantation</orgName>
								<address>
									<postCode>310003</postCode>
									<settlement>Hangzhou Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Ministry of Public Health</orgName>
								<orgName type="institution">Key Laboratory of Combined Multi-organ Transplantation</orgName>
								<address>
									<postCode>310000</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Weimin</forename><surname>Fan</surname></persName>
							<email>fanw@zju.edu.cn</email>
							<affiliation key="aff0">
								<orgName type="department">Program of Innovative Cancer Therapeutics</orgName>
								<address>
									<addrLine>Weiyang Lou</addrLine>
									<settlement>Jing Chen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Program of Innovative Cancer Therapeutics</orgName>
								<orgName type="department" key="dep2">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep3">Department of Surgery</orgName>
								<orgName type="department" key="dep4">First Affiliated Hospital</orgName>
								<orgName type="institution" key="instit1">Col- lege of Medicine</orgName>
								<orgName type="institution" key="instit2">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Key Laboratory of Organ Transplantation</orgName>
								<address>
									<postCode>310003</postCode>
									<settlement>Hangzhou Zhejiang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Ministry of Public Health</orgName>
								<orgName type="institution">Key Laboratory of Combined Multi-organ Transplantation</orgName>
								<address>
									<postCode>310000</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of Pathology and Laboratory Medicine</orgName>
								<orgName type="institution">Medical University of South Carolina</orgName>
								<address>
									<postCode>29425</postCode>
									<settlement>Charleston</settlement>
									<region>SC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Hepatobiliary and Pancreatic Surgery</orgName>
								<orgName type="department" key="dep2">Department of Surgery</orgName>
								<orgName type="department" key="dep3">First Affiliated Hospital</orgName>
								<orgName type="department" key="dep4">College of Medicine</orgName>
								<orgName type="institution">Zhejiang University</orgName>
								<address>
									<addrLine>79 Qingchun Road</addrLine>
									<postCode>310003</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1186/s12967-018-1639-8</idno>
					<note type="submission">Received: 3 April 2018 Accepted: 20 September 2018</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.1" ident="GROBID" when="2025-10-29T01:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Metastasis</term>
					<term>Invasion</term>
					<term>microRNA</term>
					<term>Hepatocellular carcinoma</term>
					<term>Bioinformatic analysis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Background: Hepatocellular carcinoma (HCC) is one of the most lethal cancer, mainly attributing to its high tendency to metastasis. Vascular invasion provides a direct path for solid tumor metastasis. Mounting evidence has demonstrated that microRNAs (miRNAs) are related to human cancer onset and progression including invasion and metastasis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods:</head><p>In search of invasion-metastasis-associated miRNAs in HCC, microarray dataset GSE67140 was downloaded from the Gene Expression Omnibus database. Differentially expressed miRNAs (DE-miRNAs) were obtained by R software package and the potential target genes were predicted by miRTarBase. The database for annotation, visualization and integrated discovery (DAVID) was introduced to perform functional annotation and pathway enrichment analysis for these potential targets of DE-miRNAs. Protein-protein interaction (PPI) network was established by STRING database and visualized by Cytoscape software. The effects of the miR-494-3p and miR-126-3p on migration and invasion of HCC cell lines were evaluated by conducting wound healing assay and transwell assay.</p><p>Results: A total of 138 DE-miRNAs were screened out, including 57 upregulated miRNAs and 81 downregulated miRNAs in human HCC tumors with vascular invasion compared with human HCC tumors without vascular invasion. 762 target genes of the top three upregulated and downregulated miRNAs were predicted, and they were involved in HCC-related pathways, such as pathway in cancer, focal adhesion and MAPK signaling pathway. In the PPI network, the top 10 hub nodes with higher degrees were identified as hub genes, such as TP53 and MYC. Through constructing the miRNA-hub gene network, we found that most of hub genes could be potentially modulated by miR-494-3p and miR-126-3p. Of note, miR-494-3p and miR-126-3p was markedly upregulated and downregulated in HCC cell lines and tissues, respectively. In addition, overexpression of miR-494-3p could significantly promote HCC migration and invasion whereas overexpression of miR-126-3p exerted an opposite effect.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p>Hepatocellular carcinoma (HCC) is a high aggressive malignancy which mortality is nearly tantamount to its incidence <ref type="bibr" target="#b0">[1]</ref>. It ranks the third most common causes of cancer-related death worldwide <ref type="bibr" target="#b1">[2]</ref>. A variety of factors lead to the fearful situation, among which metastasis is the main one. Metastasis is a complicated process involving several sequential steps, including local invasion, intravasation, transport and survival in the circulatory system, extravasation, and settlement and proliferation in a new site <ref type="bibr" target="#b2">[3]</ref>. As liver is an organ rich in blood vessel, vascular invasion is extremely frequent in clinical patients with HCC. Vascular invasion has a close connection with metastasis because it provides a direct path for cancer metastasis, and is a common precursor to occurrence of metastasis. Increasing studies have shown that cancer invasion and metastasis are closely associated with multiple biological processes, like degradation of extracellular matrix (ECM) <ref type="bibr" target="#b3">[4]</ref>, epithelial-mesenchymal transition (EMT) <ref type="bibr" target="#b4">[5]</ref>, immune evasion <ref type="bibr" target="#b5">[6]</ref>, homing of circulating cancer cells and cancer stem cells (CSCs) <ref type="bibr" target="#b6">[7]</ref>. However, the detailed molecular mechanisms that manipulate invasion and metastasis of HCC are largely unknown and need to be further elucidated. Furthermore, most of effective targeted therapeutic drugs for HCC are unavailable.</p><p>MicroRNAs (miRNAs) are a group of small endogenous single-stranded non-coding RNAs, approximately 21-25 nucleotides in length <ref type="bibr" target="#b7">[8]</ref>. MiRNAs can negatively modulate gene expression via binding to the 3′-untranslated region of messenger RNA (mRNA), thereby leading to direct degradation of mRNA or suppression of protein translation. Through this approach, miRNAs are involved in regulation of many biological processes such as proliferation, apoptosis, cell cycle and differentiation and DNA repair <ref type="bibr" target="#b8">[9]</ref>. Over the past decades, mounting studies have demonstrated that miRNA is frequently abnormally expressed in various types of cancer including HCC <ref type="bibr" target="#b9">[10]</ref>, and the dysregulation of miRNA plays a paramount role in tumorigenesis, invasion and metastasis <ref type="bibr" target="#b10">[11]</ref>. However, research exploring invasion-metastasis-associated miRNAs in HCC based on large-scale human tissues are rarely seen.</p><p>With the rapid development of gene chip and RNA sequencing technologies, Gene Expression Omnibus (GEO) gradually plays an important role in bioinformatic analysis <ref type="bibr" target="#b11">[12]</ref>. It can provide us novel clues for discovering reliable and functional miRNAs. In this study, differentially expressed miRNAs (DE-miRNAs) in HCC samples with or without vascular invasion were screened out using miRNA expression profile of GSE67140. The potential target genes of the top three most upregulated and downregulated miRNAs were predicted by miR-TarBase, and their potential functions were analyzed by gene ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Moreover, a protein-protein interaction (PPI) network of these predicted target genes and miRNAgene regulatory network were constructed by Cytoscape software. Next, the expression levels of the top 3 most upregulated and downregulated miRNAs in HCC cell lines were determined. Finally, we evaluated miR-494-3p and miR-126-3p on invasion and migration of HCC cell lines. The aim of present study is to explore and identify invasion-metastasis-associated miRNAs and their potential molecular mechanisms based on comprehensive bioinformatic analysis and related experimental validation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MiRNA microarray</head><p>In the discovery step, we only included datasets that compared the miRNA expression in invasive/metastatic HCC cell or tissue with non-invasive/metastatic HCC cell or tissue. Besides, only datasets containing more than twenty samples were included. The titles and abstracts of these datasets were screened, and the full information of the datasets of interest were further evaluated. Finally, only GSE67140 dataset was selected to further study. The dataset GSE67140 based on the platform of GPL8786 (Affymetrix Multispecies miRNA-a Array) contained 91 human HCC tumor samples without vascular invasion and 81 samples with vascular invasion was downloaded from the National Center for Biotechnology Information (NCBI) GEO database (<ref type="url" target="https://www.ncbi.nlm.nih.gov/">https ://www.ncbi.nlm.nih.gov/</ref> geo).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Screening for DE-miRNAs</head><p>Data were normalized using the normalizeBetweenArray function from R package 'LIMMA' from the bioconductor project <ref type="bibr" target="#b12">[13]</ref>. Data before and after normalization were shown in Fig. <ref type="figure" target="#fig_0">1a</ref>, b, respectively. The miRNA differential expression analysis was conducted using the limma software package in the Bioconductor package (<ref type="url" target="http://www.bioconductor.org/">http://www. bioco nduct or.org/</ref>). The related codes were put into R, and the DE-miRNAs in HCC tumor samples with vascular invasion compared to HCC tumor samples without vascular invasion were analyzed through the limma package. P-value &lt; 0.05 and |fold change (FC)| &gt; 2 were set as the thresholds for identifying DE-miRNAs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prediction of target genes</head><p>The potential target genes of the top three most upregulated and downregulated miRNAs were predicted by miRTarBase (<ref type="url" target="http://mirtarbase.mbc.nctu.edu.tw/php/index.php">http://mirta rbase .mbc.nctu.edu.tw/php/ index .php</ref>), which is an experimentally validated micro-RNA-target interactions database <ref type="bibr" target="#b13">[14]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GO and pathway analysis</head><p>The database for annotation, visualization and integrated discovery (DAVID 6.8, <ref type="url" target="http://david-d.ncifcrf.gov/">http://david -d.ncifc rf.gov/</ref>) was introduced to perform functional annotation and pathway enrichment analysis for the predicted targets of the selected 6 DE-miRNAs, including GO and KEGG pathway analysis <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>. P-value &lt; 0.05 was considered as statistically significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PPI network and miRNA-gene network construction</head><p>PPI network and miRNA-gene network were successively constructed. The target genes were first mapped to the STRING database (<ref type="url" target="http://string-db.org">http://strin g-db.org</ref>) to assess functional associations among these target genes <ref type="bibr" target="#b16">[17]</ref>. Only the interactions with a combined score &gt; 0.4 were considered as significant. Next, to obtained the hub genes, the degree of connectivity in the PPI network was analyzed by Cytoscape software (version 3.6.0), after which miRNA-hub gene network was established.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell lines and clinical samples</head><p>The human HCC cell lines HepG2, Bel-7402, HCCLM3 and SMMC7721 and normal cell line HL7702 were kindly provided by the First Affiliated Hospital of Medical College, Zhejiang University (Hangzhou, China). HepG2, Bel-7402, HCCLM3 and HL7702 were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco,12430047) supplemented with 10% fetal bovine serum (FBS; Biological Industries, 04-0101-1, Cromwell, CT, USA) and SMMC7721 was maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, 31800105, Life Technologies, Carlsbad) containing 10% FBS under a humidified atmosphere of 5% CO 2 at 37 °C. HCC tumor tissues and matched noncancerous tissues were also obtained from the First Affiliated Hospital of Medical College, Zhejiang University (Hangzhou, China).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell transfection</head><p>The miRNA mimics and negative control (purchased from RiboBio, Guangzhou, China) were transfected into HCC cell lines using Lipofectamine ™ 3000 according to the manufacturer's instruction.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RNA extraction and quantitative-PCR (qPCR)</head><p>RNAiso plus Reagent (TaKaRa, Kusatsu, Japan) was introduced to extract total RNA from HCC cell lines and clinical samples. Subsequently, miRNAs reverse transcription primers and q-PCR primers were purchased from Ribobio Co. Ltd (Guangzhou, China). Q-PCR was performed in triplicates by SYBR Premix Ex Taq (TaKaRa, RR420A). The U6 small nuclear RNA was used as the internal control. The 2 -ΔΔCT method was utilized to determine fold change in the RNA level of each sample compared with the reference sample.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The Cancer Genome Atlas database</head><p>The expression levels of miR-494-3p and miR-126-3p in HCC tissue from the Cancer Genome Atlas (TCGA) database (<ref type="url" target="https://genom">https ://genom</ref> e-cance r.ucsc.edu/) were determined. Firstly, the miRNA-sequencing data in patients of liver cancer was downloaded from the database. Then, miR-494-3p and miR-126-3p expression values were extracted, after which unpaired Student's t-test was employed to conduct statistical analysis between normal group and tumor group. A P-value &lt; 0.05 was considered as significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Wound healing assays</head><p>Cells were plated in six-well plates with 1 × 10 5 cells per well. After transfection (50 nM), the cells were grown to 100% confluence in six-well plates. Then, a micropipette tip was applied to make a cross wound. Photographs were taken by a microscopy immediately or 24 h after wounding.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Transwell assay</head><p>The cell invasion assay was performed using 24-well transwell chambers (Corning, USA). Firstly, the inserts were coated with Matrigel (BD Bioscience, USA) on the upper surface. After transfection (50 nM), 1 × 10 5 cells were suspended in 0.2 ml serum-free medium and added to the inserts. 0.6 ml medium with 20% FBS was added to the lower compartment as a chemoattractant. After incubation at 37 °C for 48 h, the cells on the upper surface of the membrane were carefully removed using a cotton bud and cells on the lower surface were successively fixed with 100% methanol and stained with 0.1% crystal violet. Five visual fields of 200× magnification of each insert were randomly selected and counted under a light microscope (Olympus, Japan).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of target gene expression using UALCAN database</head><p>UALCAN, a portal for facilitating tumor subgroup gene expression and survival analyses, provides easy access to publicly available cancer transcriptome data including TCGA <ref type="bibr" target="#b17">[18]</ref>. The database was utilized to analyze the expression levels of potential targets of miR-494-3p and miR-126-3p between normal tissue and tumor tissue. In brief, gene symbols were firstly pasted in the text area, and liver hepatocellular carcinoma dataset was chosen. Then, the expression information of each target gene could be acquired by linking to gene expression analysis result. Statistical analysis of comparison between normal group and tumor group was performed and log-rank P-value was observed in the database.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival data from Kaplan-Meier plotter</head><p>The prognostic values of miR-494-3p and miR-126-3p in HCC were analyzed using Kaplan-Meier plotter (KM plotter) database <ref type="bibr" target="#b18">[19]</ref>. In brief, the two miRNAs were entered into the database, after which Kaplan-Meier survival plots were generated and hazard ratio (HR), 95% confidence intervals (CI), log rank P-value were displayed on the webpage. P-value of &lt; 0.05 was regarded as statistically significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>The results were shown as mean ± SD. Differences between two groups were estimated using unpaired Student's t-test. A two-tailed value of P &lt; 0.05 was considered as statistically significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Identification of DE-miRNAs and their target genes</head><p>To identify DE-miRNAs of miRNA array GSE67140 downloaded from GEO, we conducted a differential expression analysis using limma software package. Based on this analysis, a total of 138 miRNAs were found to be significantly differentially expressed in HCC tumor samples with vascular invasion more than two-fold when compared to HCC tumor samples without vascular invasion, including 57 upregulated and 81 downregulated miRNAs. For better visualization, the top ten most upregulated miRNAs and top ten most downregulated miRNAs were presented in Tables <ref type="table" target="#tab_0">1</ref> and<ref type="table" target="#tab_1">2</ref>, respectively. According to fold change (FC), miR-494-3p, miR-1207-5p and miR-1268a were the top three most upregulated miRNAs; and miR-126-3p, miR-199a-3p and miR-199b-3p were the top three most downregulated miRNAs. 485 potential target genes were predicted for the three upregulated miRNAs and 277 genes for the three downregulated miRNAs by using miRTarBase. A volcano plot of these DE-miRNAs was provided in Fig. <ref type="figure" target="#fig_1">2</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GO functional enrichment analysis</head><p>Three categories of GO functional annotation analysis were performed on these potential target genes mentioned above, including biological process (BP), cellular component (CC) and molecular function (MF). As shown in Fig. <ref type="figure" target="#fig_2">3a1-a3</ref>, the enriched GO functions for target genes of the three upregulated miRNAs included the regulation of transcription, transcription, regulation of programmed cell death, regulation of cell death and regulation of apoptosis in the BP category; intracellular non-membrane-bounded organelle, non-membranebounded organelle, membrane-enclosed lumen, organelle lumen and intracellular organelle lumen in the CC category; and DNA binding, transcription regulator activity, transcription factor binding, RNA binding and sequencespecific DNA binding in the MF category. The enriched GO functions for target genes of the three downregulated miRNAs were presented in Fig. <ref type="figure" target="#fig_2">3b1-b3</ref>, involving the regulation of transcription, regulation of RNA metabolic process, positive regulation of cellular biosynthetic process, positive regulation of macromolecule metabolic process and phosphorylation in the BP category; membrane-enclosed lumen, organelle lumen, intracellular organelle lumen, nuclear lumen and cytosol in the CC category; and transcription regulator activity, adenyl ribonucleotide binding, ATP binding, purine nucleoside binding and nucleoside binding in the MF category.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>KEGG pathway enrichment analysis</head><p>To further analyze the enriched pathways of these target genes, we subsequently conducted KEGG pathway enrichment analysis. For upregulated miRNAs (Fig. <ref type="figure">4a</ref>), the enriched KEGG pathways contained pathways in cancer, focal adhesion, glioma, neurotrophin signaling pathway and insulin signaling pathway. And the enriched KEGG pathways for downregulated miRNAs (Fig. <ref type="figure">4b</ref>) included pathways in cancer, focal adhesion, MAPK signaling pathway, neurotrophin signaling pathway and chemokine signaling pathway. Interestingly, both target genes of upregulated miRNAs and targets of downregulated miRNAs were enriched in the process, focal adhesion. Accumulating evidence has demonstrated that dysregulation of focal adhesion plays a central role in cell invasion and migration <ref type="bibr" target="#b19">[20]</ref>. Therefore, 17 genes (PRKCA, HRAS, TLN1, MAP2K1, PPP1CC, PTEN, AKT1, VEGFB, MAPK1, IGF1R, CCND1, ARHGAP5, BCL2, RAC1, PPP1R12A, RAP1A, RAP1B) of upregulated miRNAs and 21 genes (PIK3CG, CAV2, FLT1, ROCK1, MET, IGF1, ITGA3, HGF, KDR, AKT1, MAPK1, CRKL, PAK4, BCL2, VEGFA, MAPK9, MAPK8, CRK, PIK3R1, AKT2, PIK3R2) of downregulated miRNAs which are involved in focal adhesion may interact with the selected 6 miRNAs, thereby modulating invasion and metastasis in HCC. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Construction and analysis of PPI network and miRNA-hub gene network</head><p>The PPI networks of target genes of the six selected DE-miRNAs were constructed using the STRING database. Data from this database revealed that lots of these target genes could interact with each other. The top ten hub genes listed in Table <ref type="table" target="#tab_2">3</ref> were screened out according to the node degree. For the upregulated miRNAs, the hub genes were TP53, AKT1, MAPK1, MYC, BCL2, HRAS, PTEN, CALM3, CDKN1A, CYCS. For the downregulated miR-NAs, the hub genes were MYC, AKT1, VEGFA, MAPK8, PIK3CG, BCL2, FGF2, KRAS, PIK3R1, SIRT1. Among these genes, TP53 and MYC demonstrated the highest node degrees, which were 80 and 42, respectively. The results suggest that TP53 and MYC may be two key targets correlated with HCC invasion and metastasis. Subsequently, the miRNA-hub gene network was constructed by cytoscape software as showed in Fig. <ref type="figure">5</ref>. From Fig. <ref type="figure">5a</ref>, we found that six (CYCS, MYC, AKT1, MAPK1, BCL2 and PTEN) in ten hub genes could be potentially modulated by upregulated miR-494-3p. 4 hub genes and 2 hub genes could be potentially regulated by miR-1207-5p and miR-1268a, respectively. Additionally, miR-126-3p could potentially target nine (PIK3R1, PIK3CG, SIRT1, BCL2, AKT1, MAPK8, VEGFA, KRAS and MYC) in ten hub genes. And 4 hub genes and 1 hub gene could be potentially modulated by miR-199a-3p and miR-199b-3p. These data supported that miR-494-3p and miR-126-3p might be two potential regulators of invasion and metastasis in HCC.</p><p>Next, we further evaluated the expression of potential targets of miR-494-3p and miR-126-3p in HCC using the UALCAN database as shown in Fig. <ref type="figure" target="#fig_3">6</ref>. The analytic results suggested that the expression of five (CYCS, MAPK1, PTEN, AKT1, BCL2) in six targets of miR-494 was significantly upregulated in HCC tissue than normal tissue whereas MYC gene was markedly downregulated. It is widely acknowledged that there is an inverse relationship between miRNA expression and target gene expression. Thus, among these detected genes, the significantly downregulated MYC may be the most potential target for the upregulated miR-494-3p. Similarly, these significantly upregulated genes including AKT1, BCL2, MAPK8, VEGFA and KRAS may be the most potential targets for the downregulated miR-126-3p in theory.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Aberrant expression and prognostic roles of miR-494-3p and miR-126-3p in HCC</head><p>Based on our previous findings, we intended to further determine the expression and prognostic roles of miR-494-3p and miR-126-3p in HCC. Firstly, we evaluated the expression of miR-494-3p and miR-126-3p in four HCC cell lines (HepG2, Bel7402, SMMC7721 and HCCLM3) compared with that in normal liver cell line (HL7702). The results presented in Fig. <ref type="figure">7a</ref>, d demonstrated that miR-494-3p expression was markedly upregulated and miR-126-3p expression were significantly downregulated in all four HCC cell lines. Of note, expression of miR-494-3p and miR-126-3p in HCCLM3 is the most upregulated and downregulated compared with other three cell lines. HCCLM3 is a high metastatic HCC cell <ref type="bibr" target="#b20">[21]</ref>, further suggesting miR-494-3p and miR-126-3p may regulate HCC metastasis. The expression of miR-1207-5p, miR-1268a, miR-199a-3p and miR-199b-3p in HCC cell lines was also detected (Additional file 1 : Figure <ref type="figure" target="#fig_0">S1</ref>). However, the expression of them was only significantly dysregulated in one or two HCC cell lines as shown in Additional file 1 : Figure <ref type="figure" target="#fig_0">S1</ref>. To some extent, the result hinted that the functional roles of miR-1207-5p, miR-1268a, miR-199a-3p and miR-199b-3p in HCC may be not as good as miR-494-3p and miR-126-3p. Besides, miR-494-3p and miR-126-3p expression in 70 pairs of clinical tumor and normal samples also demonstrated a higher expression of miR-494-3p and a lower expression of miR-126-3p in HCC tissues than normal tissues (Fig. <ref type="figure">7c,</ref><ref type="figure">f</ref> ), further hinting promoting and suppressive roles of miR-494-3p and miR-126-3p in HCC, respectively. Moreover, for miR-126-3p, similar results were obtained by downloading and analyzing HCC data from the Cancer Genome Atlas (TCGA) (Fig. <ref type="figure">7e</ref>). However, for miR-494-3p, there was no significant difference between tumor tissue and normal tissue (Fig. <ref type="figure">7b</ref>). To summarize, miR-494-3p was upregulated and miR-126-3p was downregulated in HCC, suggesting that they may play a major role in the onset and progression of HCC, especially in HCC invasion and metastasis.</p><p>KM plotter database was utilized to assess the prognostic values of the two potential miRNAs, miR-494-3p and miR-126-3p in HCC. As shown in Fig. <ref type="figure">7g</ref>, high expression of miR-494-3p was significantly correlated with worse OS, further implying that miR-494-3p is an oncogene in HCC. Figure <ref type="figure">7h</ref> indicated a favorable prognostic role of miR-126-3p in HCC. In short, all these findings suggest that miR-494-3p and miR-126-3p are aberrantly expressed in HCC and can serve as two prognostic biomarkers. Therefore, the two miRNAs, miR-494-3p and miR-126-3p were selected for further experimental excavation and research.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vitro effects of miR-494-3p and miR-126-3p on HCC migration and invasion</head><p>In the first place, miR-494-3p and miR-126-3p expression in HepG2 and HCCLM3 after transfected with miRNA mimics at final concentrations of 20, 50 and 100 nM were detected using qPCR (Additional file 2 : Figure <ref type="figure" target="#fig_1">S2</ref>). To determine the roles of miR-494-3p and miR-126-3p in HCC migration, we first performed a wound healing assay. As shown in Fig. <ref type="figure">8</ref>, wound healing assay suggested that miR-494-3p overexpression markedly enhanced HepG2 and HCCLM3 migration whereas overexpression of miR-126-3p could significantly attenuate cell migration, when compared with negative control cells. Next, a transwell invasion assay was employed to measure the effects of miR-494-3p and miR-126-3p on HCC invasion. The results presented in Fig. <ref type="figure" target="#fig_4">9</ref> demonstrated that upregulation of miR-494-3p and miR-126-3p could evidently boost and suppress cell invasion, respectively. All these data confirmed that miR-494-3p and miR-126-3p were two key regulators of HCC invasion and metastasis. Targeting miR-494-3p and miR-126-3p may represent novel approaches in treating HCC patients with vascular invasion or/and distant metastasis, thus improving the prognosis of patients with HCC.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>HCC, a high heterogeneous malignancy, which prognosis is extremely dismal, mainly attributing to its tendency to invade and metastasize. To date, effective therapeutic strategies against invasive or/and metastatic HCC is still rare. Therefore, it is imperative need to seek and develop Fig. <ref type="figure">5</ref> The regulatory network between dysregulated miRNAs and hub genes. a For upregulated miRNAs; b for downregulated miRNAs a promising therapeutic target to improve the survival of patients with advanced HCC. MiRNAs are a group of small, endogenous non-coding RNAs which possess a variety of biological functions, including modulating cell metabolism and cell survival <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>. Recent studies showed that miRNA is involved in HCC invasion and metastasis by post-transcriptionally regulating gene expression. For example, the team of Liao CG found that miR-10b promotes migration and invasion of HCC via direct repression of RhoC, uPAR and MMPs <ref type="bibr" target="#b23">[24]</ref>. In addition, Yang et al. <ref type="bibr" target="#b24">[25]</ref> suggested that miR-34a is involved in Treg cell recruitment and promotes venous metastases of HBV-positive hepatocellular carcinoma. However, systemic analysis of miRNA's roles in HCC invasion and metastasis remain absent.</p><p>In this study, we discovered some invasion-metastasisassociated miRNAs by performing a differential expression analysis on a microRNA array downloaded from GEO datasets. According to node degree, top ten hub genes of three upregulated miRNAs and three downregulated miRNAs were screened out. By constructing miRNA-gene network, we found that most of hub genes could be potentially modulated by miR-494-3p and miR-126-3p. Recent studies have suggested that miR-494-3p is linked to the occurrence and development of various types of cancer, including nasopharyngeal carcinoma, oral cancer, non-small cell lung cancer, gastric cancer and osteosarcoma <ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref>. MiR-126-3p is also reported to suppress cancer proliferation, migration and increase chemosensitivity <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref>. To the best of our knowledge, however, the roles of miR-494-3p and miR-126-3p in HCC, especially in invasion and metastasis of HCC, have not been studied. It is extremely meaningful to authenticate the functions of miR-494-3p and miR-126-3p in HCC and elucidate the mechanisms how they regulate HCC invasion and metastasis.</p><p>Q-PCR data revealed that miR-494-3p and miR-126-3p were significantly upregulated and downregulated in Fig. <ref type="figure">7</ref> The expression and prognostic roles of miR-494-3p and miR-126-3p in HCC. a The expression of miR-494-3p in four HCC cell lines (HepG2, Bel7402, SMMC7721, HCCLM3) was compared with that in one liver cell line (HL7702); b the expression of miR-494-3p in tumor tissues was compared with that in normal tissues in HCC patients from TCGA database; c the miR-494-3p expression in tumor tissues was compared with adjacent normal tissues in HCC patients from clinical; d the expression of miR-126-3p in four HCC cell lines (HepG2, Bel7402, SMMC7721, HCCLM3) was compared with that in HL7702; e the expression of miR-126-3p in tumor tissues was compared with that in normal tissues in HCC patients from TCGA database; f the miR-126-3p expression in tumor tissues was compared with adjacent normal tissues in HCC patients from clinical; g Kaplan-Meier survival curve of miR-494-3p in HCC; h Kaplan-Meier survival curve of miR-126-3p in HCC both cell lines and clinical samples. Subsequently, in vitro wound healing assay and transwell invasion assay suggested that overexpression of miR-494-3p and miR-126-3p could markedly promote and suppress HCC migration and invasion, respectively. In addition, GO annotation and KEGG pathway analysis on the predicted target genes of the top three most upregulated and downregulated miRNAs were conducted using DAVID, and the results demonstrated that some of these target genes were enriched in focal adhesion. It has been well documented that focal adhesion is closely associated with cell migration and invasion <ref type="bibr" target="#b19">[20]</ref>. Therefore, targeting these genes may be one of the mechanisms that miR-494-3p and miR-126-3p exert their effects on invasion and metastasis in HCC.</p><p>In a word, we confirmed that miR-494-3p and miR-126-3p are aberrantly expressed in both HCC cell lines and clinical samples and are two crucial regulators of HCC invasion and metastasis and can serve as prognostic biomarkers in HCC. However, there are still some limitations in this study: (1) only target genes of the top three most upregulated and downregulated miRNAs are selected for further enrichment analysis; (2) among the six selected miRNAs, only miR-494-3p and miR-126-3p are selected for experimental verification which may lead to omit some functional miRNAs; (3) a lack of research on detailed molecular mechanisms that miR-494-3p and miR-126-3p regulate invasion and metastasis of HCC is another limitation; (4) related animal studies are deficient in this study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>In conclusion, we have successfully identified two invasion-metastasis-associated miRNAs (miR-494-3p and miR-126-3p) based on bioinformatic analysis and experimental validation. The present study suggested that miR-494-3p and miR-126-3p play key roles in invasion and Fig. <ref type="figure">8</ref> Overexpression of miR-494-3p and miR-126-3p regulate HCC cell motility. a HepG2 was transfected with NC, miR-494-3p mimic, miR-126-3p mimic, respectively. Wound healing assay was performed with a 24-h recovery period; b quantification of motility from a; c HCCLM3 was transfected with NC, miR-494-3p mimic, miR-126-3p mimic, respectively. Wound healing assay was performed with a 24-h recovery period; d quantification of motility from a metastasis of HCC and can be exploited as two promising targets in treating HCC patients with vascular invasion and metastasis. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc>Fig. 1 Normalization of GSE67140 data. a Data before normalization; b data after normalization</figDesc><graphic coords="3,85.19,94.83,425.40,207.48" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc>Fig. 2 Volcano plot of the DE-miRNAs. The black dots represent miRNAs that are not differentially expressed between 91 human HCC tumor samples without vascular invasion and 81 samples with vascular invasion, and the red dots and green dots represent the upregulated and downregulated miRNAs in HCC tumor samples with vascular invasion, respectively</figDesc><graphic coords="6,66.17,94.83,215.40,203.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3</head><label>3</label><figDesc>Fig. 3 GO functions for the target genes of top three upregulated miRNAs and top three downregulated miRNAs. a1 Enriched biological process of the upregulated miRNAs; a2 enriched cellular component of the upregulated miRNAs; a3 enriched molecular function of the upregulated miRNAs; b1 enriched biological process of the downregulated miRNAs; b2 enriched cellular component of the downregulated miRNAs; b3 enriched molecular function of the downregulated miRNAs</figDesc><graphic coords="7,62.63,94.83,470.52,469.08" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 6</head><label>6</label><figDesc>Fig. 6 The mRNA expression of predicted targets of miR-494-3p and miR-126-3p from the UALCAN database. a CYCS expression; b MAPK1 expression; c PTEN expression; d AKT1 expression; e BCL2 expression; f MYC expression; g MAPK8 expression; h VEGFA expression; i KRAS expression; j PIK3CG expression; k PIK3R1 expression; l SIRT1 expression</figDesc><graphic coords="10,62.63,94.83,470.52,431.52" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 9</head><label>9</label><figDesc>Fig. 9 Overexpression of miR-494-3p and miR-126-3p regulate HCC cell invasion. a HepG2 and HCCLM3 transfected with miR-494-3p invaded more versus control cancer cells, whereas HepG2 and HCCLM3 transfected with miR-126-3p invaded less versus control cancer cells; b quantification of invasion from HepG2; c quantification of invasion from HCCLM3</figDesc><graphic coords="13,106.55,94.83,382.68,323.64" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc></figDesc><graphic coords="9,106.67,440.95,382.68,266.88" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc></figDesc><graphic coords="11,62.51,94.83,470.76,422.52" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc></figDesc><graphic coords="12,62.63,94.83,470.52,286.08" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 Top ten upregulated differentially expressed miRNAs between HCC tumor with vascular invasion and without vascular invasion</head><label>1</label><figDesc></figDesc><table><row><cell>miRNA</cell><cell>Log 2 FC</cell><cell>AveExpr</cell><cell>t</cell><cell>P value</cell><cell>adj.P.val</cell><cell>B</cell></row><row><cell>hsa-miR-494-3p</cell><cell>3.213965</cell><cell>8.547004</cell><cell>14.52827</cell><cell>9.49E-32</cell><cell>3.34E-29</cell><cell>61.55024</cell></row><row><cell>hsa-miR-1207-5p</cell><cell>2.176223</cell><cell>9.115458</cell><cell>9.917775</cell><cell>1.25E-18</cell><cell>3.21E-17</cell><cell>31.61977</cell></row><row><cell>hsa-miR-1268a</cell><cell>2.152237</cell><cell>8.776311</cell><cell>10.0675</cell><cell>4.80E-19</cell><cell>1.45E-17</cell><cell>32.56622</cell></row><row><cell>hsa-miR-1225-5p</cell><cell>2.137299</cell><cell>7.255844</cell><cell>9.334773</cell><cell>5.00E-17</cell><cell>9.42E-16</cell><cell>27.97336</cell></row><row><cell>hsa-miR-923</cell><cell>2.043838</cell><cell>11.34486</cell><cell>7.931558</cell><cell>2.61E-13</cell><cell>2.51E-12</cell><cell>19.52928</cell></row><row><cell>hsa-miR-1281</cell><cell>2.038617</cell><cell>7.431229</cell><cell>10.66035</cell><cell>1.05E-20</cell><cell>3.72E-19</cell><cell>36.34667</cell></row><row><cell>hsa-miR-1275</cell><cell>1.991306</cell><cell>6.77929</cell><cell>10.49143</cell><cell>3.14E-20</cell><cell>1.07E-18</cell><cell>35.26462</cell></row><row><cell>hsa-miR-1224-5p</cell><cell>1.982613</cell><cell>5.940673</cell><cell>9.473018</cell><cell>2.10E-17</cell><cell>4.24E-16</cell><cell>28.83197</cell></row><row><cell>hsa-miR-92b-5p</cell><cell>1.93886</cell><cell>7.353231</cell><cell>8.887235</cell><cell>8.10E-16</cell><cell>1.13E-14</cell><cell>25.22309</cell></row><row><cell>hsa-miR-572</cell><cell>1.917433</cell><cell>6.686904</cell><cell>7.419681</cell><cell>5.11E-12</cell><cell>4.21E-11</cell><cell>16.60168</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 Top ten downregulated differentially expressed miRNAs between HCC tumor with vascular invasion and without vascular invasion</head><label>2</label><figDesc></figDesc><table><row><cell>miRNA</cell><cell>Log 2 FC</cell><cell>AveExpr</cell><cell>t</cell><cell>P value</cell><cell>adj.P.val</cell><cell>B</cell></row><row><cell>hsa-miR-199a-3p hsa-miR-199b-3p hsa-miR-126-3p hsa-miR-195-5p hsa-miR-30a-5p hsa-miR-143-3p hsa-miR-100-5p hsa-miR-19b-3p hsa-miR-21-5p hsa-miR-146b-5p</cell><cell>-3.49273 -3.46525 -3.36828 -3.19533 -3.14494 -3.07332 -2.90109 -2.87469 -2.85469 -2.81179</cell><cell>7.052915 7.057111 9.212248 7.128742 7.071084 9.16678 8.128079 7.51099 5.834845 6.432729</cell><cell>-13.3399 -13.0789 -13.2869 -15.3637 -13.2253 -11.141 -10.7776 -10.8113 -14.4948 -10.1073</cell><cell>2.38E-28 1.33E-27 3.38E-28 4.02E-34 5.07E-28 4.62E-22 4.92E-21 3.96E-21 1.18E-31 3.72E-19</cell><cell>2.88E-26 1.13E-25 3.58E-26 3.41E-31 4.78E-26 2.17E-20 1.90E-19 1.60E-19 3.34E-29 1.17E-17</cell><cell>53.79083 52.08226 53.44345 66.96628 53.04028 39.44342 37.10007 37.31624 61.33273 32.81846</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 Hub genes identified in the PPI interaction</head><label>3</label><figDesc></figDesc><table><row><cell>Upregulated miRNAs</cell><cell></cell><cell cols="2">Downregulated miRNAs</cell></row><row><cell>Gene symbol</cell><cell>Degree</cell><cell>Gene symbol</cell><cell>Degree</cell></row><row><cell>TP53</cell><cell>80</cell><cell>MYC</cell><cell>42</cell></row><row><cell>AKT1</cell><cell>72</cell><cell>AKT1</cell><cell>39</cell></row><row><cell>MAPK1</cell><cell>61</cell><cell>VEGFA</cell><cell>38</cell></row><row><cell>MYC</cell><cell>51</cell><cell>MAPK8</cell><cell>35</cell></row><row><cell>BCL2</cell><cell>46</cell><cell>PIK3CG</cell><cell>35</cell></row><row><cell>HRAS</cell><cell>46</cell><cell>BCL2</cell><cell>28</cell></row><row><cell>PTEN</cell><cell>46</cell><cell>FGF2</cell><cell>22</cell></row><row><cell>CALM3</cell><cell>45</cell><cell>KRAS</cell><cell>22</cell></row><row><cell>CDKN1A</cell><cell>44</cell><cell>PIK3R1</cell><cell>21</cell></row><row><cell>CYCS</cell><cell>40</cell><cell>SIRT1</cell><cell>21</cell></row><row><cell cols="2">PPI protein-protein interaction</cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgements</head><p>This work was supported by <rs type="funder">National Natural Science Foundation of China</rs> grants (<rs type="grantNumber">81372462</rs>, <rs type="grantNumber">81572987</rs>) and the <rs type="funder">Department of Science and Technology of Zhejiang Province</rs> (<rs type="grantNumber">2014C03012</rs>). Thanks for the anonymous reviewers for their valuable comments and suggestions that helped improve the quality of our manuscript.</p></div>
			</div>
			<div type="funding">
<div><head>Funding</head><p>The <rs type="funder">National Natural Science Foundation of China</rs> (Nos. <rs type="grantNumber">81372462</rs> and <rs type="grantNumber">81572987</rs>), the <rs type="funder">Department of Science and Technology of Zhejiang Province</rs> (<rs type="grantNumber">2014C03012</rs>) and the <rs type="funder">National Science Foundation for Post-doctoral Scientists of China</rs> (No. <rs type="grantNumber">2017M621953</rs>).</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_rAe8Twq">
					<idno type="grant-number">81372462</idno>
				</org>
				<org type="funding" xml:id="_G3YUk6f">
					<idno type="grant-number">81572987</idno>
				</org>
				<org type="funding" xml:id="_KqX2b5e">
					<idno type="grant-number">2014C03012</idno>
				</org>
				<org type="funding" xml:id="_hEch2jj">
					<idno type="grant-number">81372462</idno>
				</org>
				<org type="funding" xml:id="_nv45Fm6">
					<idno type="grant-number">81572987</idno>
				</org>
				<org type="funding" xml:id="_EuGMUBt">
					<idno type="grant-number">2014C03012</idno>
				</org>
				<org type="funding" xml:id="_5ugWAKg">
					<idno type="grant-number">2017M621953</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p>Please contact author for data requests.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional files</head><p>Additional file 1: Figure <ref type="figure">S1</ref>. The expression levels of miR-1207-5p, miR-1268a, miR-199a-3p and miR-199b-3p in HCC cell lines. (A) The expression of miR-1207-5p in HCC cell lines was compared with that in normal liver cell line (HL7702); (B) the expression of miR-1268a in HCC cell lines was compared with that in HL7702; (C) the expression of miR-199a-3p in HCC cell lines was compared with that in HL7702; (D) the expression of miR-199b-3p in HCC cell lines was compared with that in HL7702. Ns represents no significance; *P &lt; 0.05; **P &lt; 0.01. Error bars represent s.d. for n = 3.</p><p>Additional file 2: Figure <ref type="figure">S2</ref>. After transfected with mimic at indicated concentration (20 nM, 50 nM and 100 nM), miR-494-3p and miR-126-3p expression levels were significantly increased in both HepG2 and HCCLM3 cell lines. Ns represents no significance; *P &lt; 0.05. Error bars represent s.d. for n = 3. MiR-494-3p and miR-126-3p expression levels were detected using q-PCR at 48 h post-transfection Abbreviations HCC: hepatocellular carcinoma; ECM: extracellular matrix; EMT: epithelial-mesenchymal transition; CSC: cancer stem cell; miRNA: microRNA; mRNA: messenger RNA; GEO: Gene Expression Omnibus; PPI: protein-protein interaction; NCBI: National Center for Biotechnology Information; DAVID: the database for annotation, visualization and integrated discovery; GO: gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; FBS: fetal bovine serum; BP: biological process; CC: cellular component; MF: molecular function.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p>WYL and WMF designed the study. WYL wrote the manuscript. JC and BSD revised and polished the manuscript. WYL, JC and BSD performed the experiments and statistical analysis of the data. DNC conducted some experiments. HLZ, DHJ, LX, CB and GQC collected clinical samples. All authors read and approved the final manuscript.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p>The authors declare that they have no competing interests.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication</head><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval and consent to participate</head><p>This study was approved by the Institutional Ethics Review Board of the First Affiliated Hospital, College of medicine, Zhejiang University, Zhejiang, China.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publisher's Note</head><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p>• fast, convenient online submission • thorough peer review by experienced researchers in your field</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>• rapid publication on acceptance</head><p>• support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>•</head><p>At BMC, research is always in progress.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Learn more biomedcentral.com/submissions</head><p>Ready to submit your research ? Choose BMC and benefit from:</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclindependent kinase 6 in mice</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zhan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1952" to="1967" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Singal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>El-Serag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2140" to="2151" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Role of miRNAs in human cancer metastasis: implications for therapeutic intervention</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Jafri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Al-Qahtani</forename><surname>Mh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Shay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Cancer Biol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="117" to="131" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Androgen-induced TMPRSS2 activates matriptase and promotes extracellular matrix degradation, prostate cancer cell invasion, tumor growth, and metastasis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Juan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Lan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Shyu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Hsiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Shun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="2949" to="2960" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">miR-106b promotes cell invasion and metastasis via PTEN mediated EMT in ESCC</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Shan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Lett</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="4619" to="4626" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis</title>
		<author>
			<persName><forename type="first">Dvf</forename><surname>Tauriello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palomo-Ponce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Stork</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berenguer-Llergo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Badia-Ramentol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Iglesias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sevillano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ibiza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Canellas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Hernando-Momblona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">554</biblScope>
			<biblScope unit="page" from="538" to="543" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Mol Med</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1337" to="1349" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">MicroRNAs: target recognition and regulatory functions</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Bartel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="215" to="233" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">MicroRNAs: processing, maturation, target recognition and regulatory functions</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Shukla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Barik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Pharmacol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="83" to="92" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">Ya-O</forename><surname>Shyu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Chien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Tsou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Transl Med</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">200</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chen</forename><forename type="middle">J</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ba-Ohoo</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Transl Med</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">134</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">NCBI GEO: archive for functional genomics data sets-update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Wilhite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ledoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Evangelista</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">F</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tomashevsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Phillippy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Holko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="991" to="995" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Use of within-array replicate spots for assessing differential expression in microarray experiments</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Smyth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Michaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Scott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2067" to="2075" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shrestha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">W</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="296" to="302" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</title>
		<author>
			<persName><forename type="first">W</forename><surname>Da Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Lempicki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Protoc</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="44" to="57" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</title>
		<author>
			<persName><forename type="first">W</forename><surname>Da Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Lempicki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored</title>
		<author>
			<persName><forename type="first">D</forename><surname>Szklarczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Franceschini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kuhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Simonovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Minguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Doerks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bork</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="561" to="568" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Chandrashekar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bashel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sah</forename><surname>Balasubramanya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Creighton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ponce-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chakravarthi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Varambally</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neoplasia</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="649" to="658" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nagy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lanczky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Menyhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gyorffy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">9227</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Hypoxia and TGF-beta1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation</title>
		<author>
			<persName><forename type="first">F</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Liang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell Int</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">54</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Side population in hepatocellular carcinoma HCCLM3 cells is enriched with stem-like cancer cells</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Xiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Lett</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="3145" to="3151" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Systematic integration of molecular profiles identifies miR-22 as a regulator of lipid and folate metabolism in breast cancer cells</title>
		<author>
			<persName><forename type="first">C</forename><surname>Koufaris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Valbuena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pomyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Tredwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Nevedomskaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Benito</forename><forename type="middle">A</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Keun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="2766" to="2776" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Down-regulation of lncRNA MEG3 promotes hypoxia-induced human pulmonary artery smooth muscle cell proliferation and migration via repressing PTEN by sponging miR-21</title>
		<author>
			<persName><forename type="first">B</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">495</biblScope>
			<biblScope unit="page" from="2125" to="2132" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">miR-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPs</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Transl Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">234</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Markowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yuan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="291" to="303" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">S</forename><surname>Mei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Nie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Nie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="6679" to="6689" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc</title>
		<author>
			<persName><forename type="first">W</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1427" to="1434" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Liborio-Kimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="151" to="157" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="6965" to="6972" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">MicroRNA-494 inhibits proliferation and metastasis of osteosarcoma through repressing insulin receptor substrate-1</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lv</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transl Res</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="3439" to="3447" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">C</forename><surname>Nie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Shang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Exp Pathol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="4745" to="4754" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">MicroRNA-126 inhibits cell proliferation in gastric cancer by targeting LAT-1</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Pharmacother</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="66" to="73" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">479</biblScope>
			<biblScope unit="page" from="91" to="96" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/ AKT/MRP1 genes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="16345" to="16355" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
